PM2.5 and Cardiovascular Health Risks.


Journal

Current problems in cardiology
ISSN: 1535-6280
Titre abrégé: Curr Probl Cardiol
Pays: Netherlands
ID NLM: 7701802

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 14 02 2023
accepted: 17 02 2023
medline: 1 5 2023
pubmed: 25 2 2023
entrez: 24 2 2023
Statut: ppublish

Résumé

PM2.5 is a frequently studied particulate matter metric, due to its wide range of identified overall adverse health effects, particularly cardiovascular health risks. However, there are no clear clinical practice guidelines for air pollution in regard to the prevention of cardiovascular health risks, since most of the current medical guidelines for CVD focus on metabolic risk factors such as hyperlipidemia or diabetes. We sought to determine the relationship between PM2.5 and cardiovascular disease, cardiovascular events, and all-cause mortality by performing a systematic review and meta-analysis. We searched Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from the database inception to December 2022 for studies that reported an association between PM2.5 and cardiovascular disease, cardiovascular events, and all-cause mortality. We used the DerSimonian & Laird random-effects method to pool hazard ratios or risk ratios separately from the included studies. Of the total 18 prospective studies, 7,300,591 individuals were followed for a median follow-up of 9 years. Compared to low long-term exposure to PM 2.5 levels, an increase in exposure to PM 2.5 levels resulted in an increase in all-cause mortality (HR 1.08 95% CI of 1.05-1.11, P < 0.05). Similarly, when compared to a low long-term exposure to PM 2.5 levels, an increase in exposure to PM 2.5 levels resulted in an increase in cardiovascular disease (HR 1.09, 95% CI of 1.00-1.18, P < 0.05) and an increase in cardiovascular disease mortality (HR 1.12, 95% CI of 1.07-1.18, P < 0.05). Increased exposure to PM 2.5 levels is significantly associated with an increased risk of all-cause mortality, cardiovascular disease, and cardiovascular disease mortality. Although federal primary and secondary standards are in place, those standards are not low enough to prevent CVD health effects. Clinicians should emphasize PM2.5 as a modifiable CV risk factors for their patients to potentially reduce the development of CV complications. A clinical action guideline is needed specifically for air pollution effects on CVD, and how to mitigate them.

Identifiants

pubmed: 36828043
pii: S0146-2806(23)00087-7
doi: 10.1016/j.cpcardiol.2023.101670
pii:
doi:

Substances chimiques

Particulate Matter 0

Types de publication

Meta-Analysis Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101670

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Chayakrit Krittanawong (C)

Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, NY. Electronic address: Chayakrit.Krittanawong@nyulangone.org.

Yusuf Kamran Qadeer (YK)

Section of Cardiology, Baylor College of Medicine, Houston, TX.

Richard B Hayes (RB)

Division of Epidemiology, Department of Population Health, NYU Grossman School of Medicine, New York, NY.

Zhen Wang (Z)

Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.

Salim Virani (S)

Section of Cardiology, Baylor College of Medicine, Houston, TX; The Aga Khan University, Karachi, Pakistan; Baylor College of Medicine, Houston, TX.

George D Thurston (GD)

Department of Environmental Medicine, New York University School of Medicine, Tuxedo, NY.

Carl J Lavie (CJ)

John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH